Previous 10 | Next 10 |
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines ...
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance,...
Praxis Precision Medicines (PRAX) announces the appointment of Tim Kelly as the company's chief financial officer, effective immediately.Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management.He has more than 20 years...
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...
The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with this event. For further details see: Praxis Precision Medicines (PRAX) Investor Presentation - Slideshow
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, ...
Praxis Precision Medicines (PRAX) has priced its public offering of 5M common shares at $18.25/share, for expected gross proceeds of ~$91.25M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used for advancement of pipeline candidates and other programs, for wor...
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...
Gainers: Curis (CRIS) +53%.Second Sight Medical Products (EYES) +44%.Summit Wireless Technologies (WISA) +39%.Barnwell Industries (BRN) +36%.Autolus Therapeutics (AUTL) +31%.Ra Medical Systems (RMED) +29%.ShotSpotter (SSTI) +23%.Ideal Power (IPWR) +22%.Minerva Neurosciences (NE...
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...